Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls-Reference-Cited by-同舟云学术

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls

Published:2020-09-14 Issue:1 Volume:60 Page:69-77
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Boekhout A. H.¹^ORCID,Rogiers A.²,Jozwiak K.¹³,Boers-Sonderen M. J.⁴,van den Eertwegh A. J.⁵,Hospers G. A.⁶,de Groot J. W. B.⁷,Aarts M. J. B.⁸,Kapiteijn E.⁹,ten Tije A. J.¹⁰,Piersma D.¹¹,Vreugdenhil G.¹²,van der Veldt A. A.¹³,Suijkerbuijk K. P. M.¹⁴,Rozeman E. A.¹,Neyns B.¹⁵,Janssen K. J.¹⁶,van de Poll-Franse L. V.¹,Blank C. U.¹

Affiliation:

1. Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

2. Centre Hospitalier Universitaire Brugmann, Brussels, Belgium

3. Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany

4. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands

5. Amsterdam University Medical Centre, Amsterdam, The Netherlands

6. Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands

7. Isala Oncology Center, Zwolle, The Netherlands

8. Department of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands

9. Leiden University Medical Centre, Leiden,The Netherlands

10. Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands

11. Medical Spectrum Twente, Enschede,The Netherlands

12. Department of Internal Medicine, Maxima Medical Centre, Eindhoven,The Netherlands

13. Erasmus University Medical Centre, Rotterdam, The Netherlands

14. Department of Medical Oncology, University Medical Cancer Center, Utrecht, The Netherlands

15. Universitair Ziekenhuis Brussel, Brussel, Belgium

16. Bristol-Myers Squibb, Utrecht, The Netherlands

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1818823

Reference51 articles.

1. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2. Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

3. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

4. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

5. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival is not enough: understanding the mental burden of cutaneous melanoma;British Journal of Dermatology;2024-02-03

2. The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy;Seminars in Oncology Nursing;2024-02

3. Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression;British Journal of Dermatology;2024-01-10

4. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study;The Journal of Dermatology;2023-12-11

5. Longitudinal evaluation of health-related quality of life after removal of high-risk melanoma in a setting where adjuvant therapy is not available;Archives of Dermatological Research;2023-12-07